Although, the rate of neutropenia was higher with the PEG-IFN-α2a as compared to PEG-IFN-α-2b, proportion of patients requiring dose modification or drug withdrawal was similar with the two types of PEG-IFN administered [16]. This evidence concerns the gene IFNA1 and neutropenia.